Clinicopathologic analysis of uterine sarcomas from a single institution in the Canary Islands.
OBJECTIVE
To evaluate the clinicopathologic data and prognostic factors for patients with uterine sarcomas treated at a single institution, with special emphasis on malignant mixed müllerian tumors (MMMT).


METHODS
Medical and anatomic pathology records were reviewed. Survival rates were analyzed using the Kaplan-Meier method.


RESULTS
The study included 89 patients: 48.4% with MMMT; 22.4% with leiomyosarcomas; 20.2% with endometrial stromal sarcomas; and 9% with adenosarcomas. FIGO stages I, II, III, and IV were identified in 57.3%, 9.0%, 22.5%, and 7.8% of patients respectively. Event-free survival rates after 2, 5, and 10 years were 70%, 61%, and 55% respectively, with a median time of 90 months (95% CI, 41-140 months). Overall survival rates after 2, 5, and 10 years were 50%, 45%, and 39% respectively, with a median time of 43 months (95% CI, 3-83 months). Multivariate analysis showed that stage, histology, tumor size, and parity had an independent influence on overall survival.


CONCLUSIONS
MMMT are the most aggressive tumors and their behavior strongly resembles that of high-grade endometrial adenocarcinoma. Prognostic factors affecting survival were stage, histology, tumor size, and parity.
Benito
Virginia
V
Gynecologic Oncology Department, University Hospital of Canary Islands, Avda. Marítima del Sur s/n, Las Palmas de Gran Canaria, Spain. virginia.benito@yahoo.es
Lubrano
Amina
A
Arencibia
Octavio
O
Andújar
Miguel
M
Alvarez
Eva
E
Medina
Norberto
N
Falcón
Juan Miguel
JM
Falcón
Orlando
O
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D053208:Kaplan-Meier Estimate; D008875:Middle Aged; D018200:Mixed Tumor, Mullerian / Q000473:pathology* / Q000628:therapy; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D011379:Prognosis; D012189:Retrospective Studies; D012509:Sarcoma / Q000473:pathology* / Q000628:therapy; D013030:Spain; D015996:Survival Rate; D016896:Treatment Outcome; D014594:Uterine Neoplasms / Q000473:pathology* / Q000628:therapy